Retraction to: npj Vaccines https://doi.org/10.1038/s41541-025-01145-6, published online 24 May 2025
The Editor-in-Chief has retracted this article. After publication the Editor-in-Chief was made aware that this article contains material that overlaps with1,2,3,4,5,6,7. Additional concerns were raised regarding citations that do not support certain claims made in the text.
Adewunmi Akingbola and Petra Mariaria agree with this retraction. Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi, and Joel Chuku have not responded to correspondence regarding this retraction.
References
Wang, Y. et al. Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines. Front. Cell. Infect. Microbiol. 14, 1412478 (2024).
Stepanova, E. et al. Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza. Virol. J. 21, 82 (2024).
Ye, Q. et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines 7, 84 (2022).
Domnich, A. et al. COVID-19 and seasonal influenza vaccination: cross-protection, co-administration, combination vaccines, and hesitancy. Pharmaceuticals 15, 322 (2022).
Focosi, D. From co-administration to co-formulation: the race for new vaccines against COVID-19 and other respiratory viruses. Vaccines 11, 109 (2023).
Moderna Press Release (4 October 2023): News Release https://feeds.issuerdirect.com/news-release.html?newsid=7525841703943502&symbol=MRNA
Pfizer Press Release (16 August 2024): [Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age Pfizer https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-mrna-based-combination
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Akingbola, A., Adegbesan, A., Adegoke, K. et al. Retraction Note: Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19. npj Vaccines 10, 265 (2025). https://doi.org/10.1038/s41541-025-01353-0
Published:
Version of record:
DOI: https://doi.org/10.1038/s41541-025-01353-0
